A key limiting factor impacting the success of cell transplantation for Parkinson's disease is the survival of the grafted cells, which are often short lived. The focus of this study was to examine a novel strategy to optimize the survival of exogenous fetal ventromesencephalic (VM) grafts by treatment with the p53 inhibitor, pifithrin-α (PFT-α), to improve the biological outcome of parkinsonian animals. Adult male Sprague-Dawley rats were given 6-hydroxydopamine into the left medial forebrain bundle to induce a hemiparkinsonian state. At 7 weeks after lesioning, animals were grafted with fetal VM or cortical tissue into the lesioned striatum and, thereafter, received daily PFT-α or vehicle injections for 5 days. Apomorphine-induced rotational behavior was examined at 2, 6, 9, and 12 weeks after grafting. Analysis of TUNEL or tyrosine hydroxylase (TH) immunostaining was undertaken at 5 days or 4 months after grafting. The transplantation of fetal VM tissue into the lesioned striatum reduced rotational behavior. A further reduction in rotation was apparent in animals receiving PFT-α and VM transplants. By contrast, no significant reduction in rotation was evident in animals receiving cortical grafts or cortical grafts + PFT-α. PFT-α treatment reduced TUNEL labeling and increased TH + cell and fiber density in the VM transplants. In conclusion, our data indicate that early postgrafting treatment with PFT-α enhances the survival of dopamine cell transplants and augments behavioral recovery in parkinsonian animals.
INTRODUCTION
important mediator for cell death in experimental parkinsonian animals. Treatment with a p53 inhibitor or suppression of p53 expression limits neuronal dysfunc-Parkinson's disease (PD) is a progressive neurodegenerative disease that involves the loss of dopaminergic tion and cell death induced by exposure to dopaminergic neurotoxins. neurons in the A9 (substantia nigra, SN) region of the midbrain. Multiple animal models of PD have shown Apoptotic (programmed) cell death of midbrain DA neurons is a natural physiological process during perina-that the loss of these dopaminergic cells involves apoptosis and involvement of p53-dependent cell death. For tal development that permits the selective elimination of cells that have not correctly integrated and made appro-example, administration of the dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA) increases p53 mRNA priate contacts within the basal ganglion. In rats, for instance, there are two waves of apoptotic DA neuronal and protein expression (13) and activates p53 upregulated modulator of apoptosis (PUMA), a target gene for death occurring at P2 and P14 (19) . It is thought that this apoptotic process is similarly maintained in grafted p53 (1, 18) . Similarly, the dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) enhances dopaminergic cells derived from fetal ventromesencephalic (VM) tissue. Although clinical and preclinical stud-the expression of the proapoptoic protein BAX, reduces tyrosine hydroxylase (TH) protein levels, and depletes ies have shown that transplantation of fetal VM cells integrate and restore dopaminergic functions in parkin-dopamine (DA) (7) . These actions were antagonized by treatment with a synthetic p53 inhibitor pifithrin-α sonian animals (2), over 60-90% of embryonic dopaminergic cells die after transplantation. The death of (PFT-α) (7) . Transgenic mice with a knockout of the p53 gene were resistant to MPTP neurotoxicity (24) . To-these grafted cells likewise involves apoptosis as terminal deoxynucleotidyl transferase-mediated dUTP nick-gether, these data suggest that activation of p53 is an 1352 CHOU ET AL. end labeling (TUNEL) activity within VM grafts was 6-OHDA Lesioning enhanced within the first 4 and 7 days after transplanta-Rats were anesthetized with chloral hydrate (400 mg/ tion to unilaterally 6-OHDA-lesioned rats (20,21). Treatkg, IP) and placed in a stereotaxic frame. 6-OHDA (2.27 ment with the caspase-3 inhibitory peptide, Ac-YVADµg/µl × 5 µl in 0.9% NaCl containing 0.2 mg/ml CMK, increased the survival of embryonic VM cells in ascorbic acid) was unilaterally injected into the medial culture (20). This protective response to Ac-YVADforebrain bundle (−4.4 mm AP, 1.2 mm ML relative to CMK was not consistent in vivo. One report indicated bregma, and 8.4 mm below skull) over 4 min. that AC-YVAD-CMK, added to VM cell suspensions Behavior Measurement prior to grafting, did not augment survival of TH-immunoreactive (TH-ir) cells in the transplant (21). There are Rotational behavior (14, 15) was evaluated using a several possibilities for this discrepancy. For example, multichannel rotometer system (RotoMax, AccuScan Inthe time course of apoptosis within VM cell suspension struments, Inc). Animals were individually placed in the grafts can last up to 7 days after grafting (21). Exposure test cylinder. Four weeks after 6-OHDA lesioning, all to caspase inhibitors prior to transplantation may not be animals were challenged with apomorphine (0.05 mg/ able to suppress apoptotic cell death several days after kg, SC). Animals that rotated in excess of 300 turns/h grafting, and systemic administration of additional pepwere selected for subsequent VM or cortical transplantatide is compromised by limited brain entry. It is addition at 7 weeks after lesioning. Apomorphine-induced tionally possible that apoptosis in the transplant can be rotation was reexamined at 2, 6, 9, and 12 weeks after mediated through non-caspase-dependent pathways. Curtransplantation. rently, it remains to be elucidated whether prolonged
Grafting Procedures and Administration of PFT-α treatment with antiapoptotic agents other than caspase After Transplantation inhibitors can improve the survival of VM transplants in vivo.
Under chloral hydrate (400 mg/kg, IP) anesthesia, 6-Previous studies have demonstrated that the p53 inac-OHDA-lesioned animals were implanted with fetal cortivator, PFT-α, inhibits the translocation of p53 to mitotical (from parietal and frontal regions) or VM tissue chondria and the nucleus, prevents the binding of p53 to (two pieces, approximately 1 mm 3 each) directly into the specific DNA sites, and suppresses the apoptotic caslesioned striatal parenchyma (+0.5 mm AP, 2.5 mm ML cade. As PFT-α is a small lipophilic compound that relative to bregma, and 5.5 mm DV to the dural surface) readily crosses the blood-brain barrier (5, 9) , systemiusing a 20-gauge implantation cannula (22,27). VM or cally administered PFT-α can reach brain parenchyma cortical tissue samples were harvested from embryos at and suppress apoptosis of neural cells. We have recently 15 or 17 days of gestation. Tissues were then placed in demonstrated that repeated systemic administration of Hanks solution containing either PFT-α [1-(4-methyl-PFT-α optimizes the survival of endogenous neuroprophenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazgenitor cells, reduces the p53 target gene PUMA expresolyl)ethanone hydrobromidebenzothiazolyl)ethanone hysion in the subventricular zone, and provides functional drobromide >99.9% purity] at concentration of 0.04 mg/ improvement at 1 week after transient middle cerebral ml or vehicle [dimethyl sulfoxide (DMSO)] for about artery occlusion in stroke rats (16) . These data suggest 5 min before transplantation. Thereafter, animals were that systemic administration of PFT-α may prove valutreated with PFT-α (2 mg/kg/day, IP) or 10% DMSO in able for suppressing the cell death of precursor cells and, saline (0.5 ml/100 g/day, IP) for 5 consecutive days thereby, enhance the survival of DA graft cells and imstarting from the day of transplantation. prove functional outcome in parkinsonian animals.
TH Immunoreactivity In this study, we systemically administered PFT-α for 5 days following the transplantation of embryonic Animals were euthanized 4 months after transplantation. TH immunoreactivity was utilized to localize cate-VM cells into 6-OHDA-lesioned rats. Our data suggest that PFT-α treatment suppressed cell death, increased cholaminergic neurons and fibers. Serial sections of the entire brain were cut at 25 µm thickness in a cryostat. survival of TH + cells, enhanced TH neurite outgrowth from VM grafts, and augmented behavioral recovery.
One series from every sixth section was stained using TH antibody. In order to control for staining variability, MATERIALS AND METHODS specimens from all experimental groups were included Animals in every batch and reacted together in a net well tray under the same conditions. Sections were rinsed in 0.1 A total of 32 adult male Sprague-Dawley rats (200-250 g) were used in this study. The use of animals was M phosphate buffer (PB), blocked with 4% bovine serum albumin (BSA) and 0.3% Triton X-100 in 0.1 M approved (ASP CNRB-91) by the Animal Care and Use Committee, National Institute on Drug abuse, IRP.
PB. Sections were then incubated in a primary antibody solution mouse monoclonal anti-TH diluted in 4% BSA mals were separated (six rats per group) into four groups (specifically, VM + veh, VM + PFT-α, cortex + veh, and 0.3% Triton X-100 in 0.1 M PB, concentration 1: 100 (Chemicon, Temecula, CA) for 17-19 h at 4°C. and cortex + PFT-α) to equalize group rotational behavior at 4 weeks after 6-OHDA lesioning. There was thus Sections were rinsed in 0.1 M PB and incubated in biotinylated horse anti-mouse IgG in the buffer (1:200; no difference in apomorphine-induced rotation prior to transplantation among all groups (p = 0.968, one-way Vector Laboratories, Burlingame CA) for 1 h, followed by incubation for 1 h with avidin-biotin-horseradish per-ANOVA). The rotational behavior was reexamined at 2, 6, 9, and 12 weeks after transplantation ( Fig. 1) . Using oxidase complex. Staining was developed with 2,3′-diaminobenzidine tetrahydrochloride (0.5 mg/ml in 50 mM a three-way ANOVA, we determined that transplantation of fetal VM cells, compared to fetal cortical tissue, Tris-HCl buffer 7.4). Control sections were incubated without primary antibody. Sections were mounted on significantly reduced apomorphine-mediated contralateral rotation [F(1, 80 = 10.735, p < 0.002]. Treatment slides, and cover slipped.
with PFT-α did not alter rotation [F(1, 80) = 1.562, p = TUNEL Histochemistry 0.215, three-way ANOVA]. However, there was a sig-Animals were euthanized at 2 h after the final injecnificant interaction between PFT-α treatment and VM tion of either PFT-α or vehicle on day 5 posttransplantatransplantation [F(1, 80) = 6.086, p = 0.016, three-way tion. The brains were removed, frozen in isopentane on ANOVA]. Post hoc Newman-Keuls analysis indicated dry ice, and stored at −80°C. For sectioning, frozen that treatment with PFT-α, compared to vehicle, signifibrains were cut into 25-µm sections using a cryostat.
cantly reduced rotation in animals receiving VM grafts The sections were mounted onto Superfrost/Plus micro-(p = 0.010). Such a difference was not found in animals scope slides (Cat. 12-550-15; Fisher, PA) and air dried.
receiving cortical transplants treated with PFT-α or sa-A standard TUNEL procedure for frozen tissue sections line (p = 0.392). with minor modifications was performed (6) . Briefly, TH Immunostaining slide-mounted sections were rinsed in 0.5% Triton X-100 in 0.01 M PB for 20 min at 80°C to increase perme-TH immunoreactivity was examined at >4 months ability of the cells. To label damaged nuclei, 100 µl of after transplantation in 24 rats. A near complete deplethe TUNEL reaction mixture was added onto each samtion of TH immunoreactivity was found in the lesioned ple in a humidified chamber followed by a 60-min incu-SN area ( Fig. 2A-D) . Transplantation of fetal VM (Fig.  bation at 37°C . Procedures for negative controls were 2A, B) or cortical tissue (Fig. 2C, D2 ), as well as treatcarried out as described in the manufacturer's manual ment with PFT-α ( Fig. 2A , C) or vehicle (Fig. 2B, D studies (25) , a reduction of TH fiber density was also found in the lesioned striatum away from the site of Cell Counting transplant. At the graft site, TH + dendrites or cell bodies TH + cells in each brain slice were counted every 0. 15 were not found in the lesioned animals that received cormm from 0.48 to −0.42 mm relative to bregma. All cells tical transplants and given saline (n = 6, Fig. 2E ) or with visualized nuclei were counted. TUNEL activity PFT-α (n = 6, Fig. 2F ) injections. In contrast, TH fibers was examined at 0.48, 0.18, and −0.27 mm sections or cell bodies were found in animals receiving VM from bregma. TUNEL activity was measured using pixel transplantation with (n = 6, Fig. 3B , D) or without (n = density as described previously (3,16). All cell counts 6, Fig. 3A , C) PFT-α. Typical TH immunostaining of a were made by blinded observers.
VM graft is shown in Figure 3B . TH cell bodies and neurites mainly resided in the graft area. Treatment with Statistical Analysis PFT-α substantially enhanced the density of TH immu-ANOVA and post hoc Newman-Keuls test were used noreactivity in the VM transplants ( Fig. 3B vs. A) . The for statistical comparison. Data are presented as mean ± number of TH cell bodies in the transplant was also sig-SEM. Probability level of less than 5% (p < 0.05) was nificantly increased by PFT-α [F(1, 63) = 10.319, p = considered to be significant. 0.002, two-way ANOVA) ( Fig. 4) . At higher magnification, treatment with PFT-α not only increased the num-RESULTS ber of TH cells but also their arborization ( Fig. 3D vs. Behavior C). TH + fibers or dendrites were more densely spread amongst TH cell bodies in the graft area after PFT-α Behavioral analysis was performed on a total of 24 animals. All possessed unilateral 6-OHDA lesions. Ani-treatment ( Fig. 3B vs. A) . Striatal transplantation of VM cells or administration PFT-α did not alter TH immuno-administration to animals undergoing transplantation. We found that treatment with PFT-α for 5 days signifi-reactivity in the lesioned nigra ( Fig. 2A-D) .
cantly improved the survival of grafts, enhanced their TUNEL Labeling viability, and potentiated functional recovery in hemiparkinsonian animals. Our results differ from a previous Eight 6-OHDA lesioned rats were grafted with VM transplants, and then treated with PFT-α (n = 4) or vehi-study showing that the peptide caspase inhibitor, Ac-YVAD-CMK, which has minimal blood-brain barrier cle (n = 4) for 5 days, euthanized, and prepared for TUNEL histochemistry. In all animals, an increase in permeability, did not augment survival of TH-ir neurons in VM grafts (17) . In the study by Marchinoni et al. TUNEL labeling was found in the transplants. Treatment with PFT-α reduced TUNEL activity in the grafts (17) , Ac-YVAD-CMK was added to the graft cell suspension only prior to transplantation. In contrast, we in- (Fig. 5) . The optical density of TUNEL was further analyzed in 0.48, 0.18, and −0.27 mm sections from bregma cluded PFT-α in the graft media before transplantation and also administered PFT-α for 5 consecutive days in all animals (Fig. 6 ). PFT-α, compared to vehicle, significantly reduced TUNEL labeling in the graft [F(1, 24) = after transplantation. It is possible that protection of the transplant requires continuous administration of an apo-7.312, p = 0.012, two-way ANOVA] (Fig. 6) .
ptotic inhibitor for several days after transplantation, DISCUSSION which is achievable with PFT-α because apoptosis in grafts lasts up to a week after transplantation (20,21), To overcome the extensive apoptosis associated with dopaminergic cell transplantation into the brain, a funda-analogous to normal developmental programmed cell death. mental shortcoming in developing this strategy for PD treatment, in the current study we used a p53 inhibitor, We, and others, have recently reported that treatment with PFT-α enhanced the survival of nondopaminergic PFT-α, to increase the survival and viability of VM grafts in hemiparkinsonian animals. As PFT-α is a small cells after ischemic brain injury (12, 16) . PFT-α suppressed TUNEL labeling of these cells through the in-molecular weight, lipophilic compound that readily enters the brain (5, 9) , it is amenable to repeated systemic hibition of p53 target genes, such as PUMA (16). transplants. Likewise, behavioral improvement was not found in animals receiving cortical transplants in combination with a p53 inhibitor. Our unpublished observations also indicated that treatment with PFT-α alone, compared to vehicle, did not alter apomorphine-induced rotation in unilaterally 6-OHDA-lesioned animals with no grafts (p = 0.934). These data suggest that augmented functional improvement depends on the presence of both VM transplant and PFT-α. Because PFT-α did not increase behavioral recovery in the lesioned animals receiving cortical grafts or no graft but enhanced behavioral recovery in animals receiving VM graft, PFT-α synergistically, but not additively, potentiated the recovery after fetal VM transplantation.
Using TH immunostaining, we found that the trans- much more densely spread among TH cell bodies in the graft area after PFT-α treatment at 4 months after grafting. These data suggest that suppression of p53 activity Similarly, in this study, we found that the survival of exogenous VM grafts was also enhanced. At 5 days after not only has protective effects on the DA cell bodies, but results in enhanced the outgrowth of dendrites. grafting, there was an increase in TUNEL labeling at the graft site, which was reduced by PFT-α. Posttransplan-Whether this effect resulted from a direct action of p53 on dendrite outgrowth or indirect actions related to im-tation treatment with PFT-α additionally potentiated recovery of motor function in 6-OHDA-lesioned animals proved cell viability remains to be determined. Nevertheless, this outcome is similar to the trophic response receiving VM transplantation for 12 weeks, indicating that the improved cell survival afforded by PFT-α was to glial cell line-derived neurotrophic factor (GDNF) in dopamine transplants (8, 28) . In this regard, we pre-of physiological relevance. These data suggest that suppressing apoptosis in the early period (specifically, 5
viously reported that coadministration of GDNF enhances the survival of VM grafts and TH fiber out-days after grafting) is sufficient to provide enhanced long-term behavioral recovery for up to 12 weeks. growth (23, 26) . Because GDNF can induce protection via antiapoptosis in various injury models (4,10), it is Of note, 5-day PFT-α treatment did not completely abolish TUNEL labeling in transplants, suggesting that possible that common mechanisms may be involved in GDNF and PFT-α-mediated protection. the apoptotic reaction is only partially antagonized by PFT-α. Increasing the dose or duration of PFT-α treat-In conclusion, our data suggest that early and continuous administration of PFT-α prolongs the survival and ment, or combinations with other antiapoptotic agents may maximize the protection, particularly should other function of dopaminergic cell transplants in parkinsonian animals. Posttreatment with PFT-α may therefore antagonists act via non-p53 mechanisms. Previous studies have demonstrated that PFT-α suppresses dopamin-be considered a viable therapeutic strategy to optimize cell transplantation. ergic toxin-mediated neurodegeneration (7) . This protective response was found only when PFT-α was given
